Foghorn Therapeutics Inc.2024财年第三财季实现净利润-19.12百万美元，同比减少33.24%

市场透视11-11

11月11日，Foghorn Therapeutics Inc.（FHTX.US）公布财报，公告显示公司2024财年第三财季净利润为-19.12百万美元，同比减少33.24%；其中营业收入为7.81百万美元，同比减少55.32%，每股基本收益为-0.31美元。从资产负债表来看，Foghorn Therapeutics Inc.（FHTX.US）总负债3.37亿美元，其中短期债务8.77百万美元，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2482267886?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-11 00:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2482267886","market":"us","top_or_hot":-1,"title":"Foghorn Therapeutics Inc.2024财年第三财季实现净利润-19.12百万美元，同比减少33.24%","media":"市场透视","content":"<div>\n<p>11月11日，Foghorn Therapeutics Inc.（FHTX.US）公布财报，公告显示公司2024财年第三财季净利润为-19.12百万美元，同比减少33.24%；其中营业收入为7.81百万美元，同比减少55.32%，每股基本收益为-0.31美元。从资产负债表来看，Foghorn Therapeutics Inc.（FHTX.US）总负债3.37亿美元，其中短期债务8.77百万美元，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111000031a229e370&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Foghorn Therapeutics Inc.2024财年第三财季实现净利润-19.12百万美元，同比减少33.24%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFoghorn Therapeutics Inc.2024财年第三财季实现净利润-19.12百万美元，同比减少33.24%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-11 00:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111000031a229e370&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>11月11日，Foghorn Therapeutics Inc.（FHTX.US）公布财报，公告显示公司2024财年第三财季净利润为-19.12百万美元，同比减少33.24%；其中营业收入为7.81百万美元，同比减少55.32%，每股基本收益为-0.31美元。从资产负债表来看，Foghorn Therapeutics Inc.（FHTX.US）总负债3.37亿美元，其中短期债务8.77百万美元，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111000031a229e370&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FHTX","symbol_name":"Foghorn Therapeutics Inc.","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111000031a229e370&s=b","article_id":"2482267886","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111000031a229e370&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2482267886","pubTimestamp":1731254422,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"11月11日，Foghorn Therapeutics Inc.公布财报，公告显示公司2024财年第三财季净利润为-19.12百万美元，同比减少33.24%；其中营业收入为7.81百万美元，同比减少55.32%，每股基本收益为-0.31美元。机构评级：截至2024年11月11日，当前有6家机构对Foghorn Therapeutics Inc.目标价做出预测，其中目标均价为16.00美元，其中最低目标价为9.00美元，最高目标价为20.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"FHTX":"Foghorn Therapeutics Inc.","LENZ":"Therapeutics"},"translate_title":"Foghorn Therapeutics Inc. achieved net profit of-19.12 million in the third fiscal quarter of fiscal 2024, a year-on-year decrease of 33.24%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FHTX":1,"LENZ":1},"content_text":"11月11日，Foghorn Therapeutics Inc.（FHTX.US）公布财报，公告显示公司2024财年第三财季净利润为-19.12百万美元，同比减少33.24%；其中营业收入为7.81百万美元，同比减少55.32%，每股基本收益为-0.31美元。从资产负债表来看，Foghorn Therapeutics Inc.（FHTX.US）总负债3.37亿美元，其中短期债务8.77百万美元，资产负债比为0.92，流动比率为0.05。机构评级：截至2024年11月11日，当前有6家机构对Foghorn Therapeutics Inc.目标价做出预测，其中目标均价为16.00美元，其中最低目标价为9.00美元，最高目标价为20.00美元。公司简介：Foghorn Therapeutics Inc 致力于发现和开发一类新的药物，这些药物针对染色质调节系统中基因决定的依赖性。 其专有的基因流量控制平台对染色质调节系统的各个组成部分如何相互作用提供了一个综合的、机械的理解，使其能够识别、验证和潜在的系统内药物靶点。 该公司正在开发 FHD-286（一种选择性变构 ATP 酶抑制剂）和 FHD-609（一种蛋白质降解剂）， 用于治疗血液系统癌症和实体瘤。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2482267886"}